Impax Asset Management Group plc Grows Stock Position in Agilent Technologies, Inc. (NYSE:A)

Impax Asset Management Group plc grew its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 8.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,667,616 shares of the medical research company's stock after purchasing an additional 203,234 shares during the quarter. Agilent Technologies accounts for about 1.6% of Impax Asset Management Group plc's holdings, making the stock its 19th biggest holding. Impax Asset Management Group plc owned about 0.93% of Agilent Technologies worth $396,088,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory purchased a new stake in shares of Agilent Technologies during the third quarter worth approximately $28,000. Crewe Advisors LLC raised its holdings in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company's stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Ridgewood Investments LLC purchased a new stake in shares of Agilent Technologies during the 2nd quarter worth $29,000. Fortitude Family Office LLC grew its stake in shares of Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock worth $35,000 after purchasing an additional 95 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in Agilent Technologies by 29,300.0% in the first quarter. Larson Financial Group LLC now owns 294 shares of the medical research company's stock valued at $43,000 after buying an additional 293 shares during the last quarter.

Agilent Technologies Price Performance

NYSE A traded up $2.78 during trading hours on Monday, reaching $139.65. The company's stock had a trading volume of 1,792,737 shares, compared to its average volume of 1,683,184. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The company's 50-day moving average is $139.73 and its two-hundred day moving average is $138.08. Agilent Technologies, Inc. has a fifty-two week low of $104.09 and a fifty-two week high of $155.35. The stock has a market cap of $40.13 billion, a PE ratio of 28.40, a PEG ratio of 6.26 and a beta of 1.07.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.43 EPS. Analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were issued a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.68%. Agilent Technologies's dividend payout ratio (DPR) is presently 19.50%.

Insider Activity

In other news, SVP Dominique Grau sold 9,990 shares of the firm's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares of the company's stock, valued at approximately $3,497,110. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,995 shares of company stock valued at $1,739,510 over the last 90 days.

Analyst Ratings Changes

A has been the topic of several recent analyst reports. Barclays increased their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an "underweight" rating in a research note on Tuesday, October 15th. UBS Group raised their price objective on Agilent Technologies from $141.00 to $150.00 and gave the stock a "neutral" rating in a report on Thursday, August 22nd. Stifel Nicolaus reissued a "buy" rating and issued a $151.00 target price on shares of Agilent Technologies in a report on Monday, August 26th. TD Cowen increased their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a "buy" rating in a research note on Thursday, August 22nd. Finally, Citigroup lifted their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a "buy" rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $144.36.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.